The group wants to improve on its own Welireg in a new phase 3 trial.
ApexOnco Front Page
Recent articles
Replimune gets a second chance, while Sarclisa could go subcutaneous.
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
Tecvayli and Hernexeos might get speedy approval decisions.
RMC-5127 becomes the company’s fourth clinical project.
The line-up is revealed to include Merck & Co and J&J itself.
The group also discontinues a mystery asset, and a Tecentriq trial in periadjuvant lung cancer.
Bristol will test the bispecific in two new lung indications.
